Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WellPoint Cancer Drug Pathways Program Aims To Save 4% In Annual Costs

This article was originally published in The Pink Sheet Daily

Executive Summary

When it is fully operational in all 14 WellPoint states, more than 21 million members will be eligible for the initiative to standardize cancer prescribing and lower drug costs.

You may also be interested in...



Multiple Myeloma Would Make Good Guinea Pig For Oncology Cost Control

With an array of high quality drugs and preference for stacked combo therapy in multiple myeloma, the disease is poised to become a testing ground for cost containment in oncology.

Cancer Pathways Will Help Inform Drug Performance Measures, Payers Say

Over the last two years, UnitedHealthcare and Aetna have launched cancer pathway programs with the overall goals of standardizing and improving care and lowering cost. Drug therapy is a key focus.

Part B Drugs At Home: Medicare Policy Responds To COVID-Driven Access Concerns

Temporary policy may open door to longer term change as Medicare allows reimbursement of at-home administration of non-hospital drugs covered by Part B under a recently-released regulation aiding at encouraging telehealth during the coronavirus outbreak.

Topics

Related Companies

UsernamePublicRestriction

Register

PS077267

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel